Results from STEP UP further strengthen the clinical profile of semaglutide for the treatment of obesity, in addition to the health benefits already established with Wegovy, said Martin Holst Lange, executive vice president for Development at Novo Nordisk, in a statement from the company
Combining the two may extend nausea duration and intensity beyond what either substance produces alone
(2002) Nutritional ergogenic aids and exercise performance, Nutrition Research Reviews, 15(2), pp
J Parenter Enteral Nutr 2003
Compounded versions of both are available through telehealth providers and compounding pharmacies with a prescription
(Off-label use is when doctors prescribe a drug for a purpose other than what its approved for.) Nausea is one of the most common side effects of Ozempic